%	O
%	O
TITLE	O

The	O
role	O
of	O
human	O
papillomavirus	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
:	O
A	O
case	O
control	O
study	O
on	O
a	O
southern	O
Chinese	O
population	O
.	O

%	O
%	O
ABSTRACT	O

HPV	O
plays	O
a	O
role	O
in	O
the	O
development	O
of	O
a	O
portion	O
of	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
HNSCC	O
)	O
,	O
but	O
only	O
limited	O
information	O
on	O
its	O
role	O
in	O
southern	O
Chinese	O
population	O
is	O
available	O
.	O

A	O
multicenter	B-Study_Type
case	I-Study_Type
-	I-Study_Type
control	I-Study_Type
study	I-Study_Type
was	O
conducted	O
.	O

HPV	O
type	O
,	O
viral	O
integration	O
,	O
E6	O
/	O
7	O
mRNA	O
expression	O
status	O
,	O
and	O
TP53	O
mutation	O
were	O
determined	O
.	O

A	B-Study_Cohort
total	I-Study_Cohort
of	I-Study_Cohort
228	I-Study_Cohort
HNSCC	I-Study_Cohort
were	I-Study_Cohort
recruited	I-Study_Cohort
including	O
137	O
(	O
60	O
.	O
1	O
%	O
)	O
oral	O
SCC	O
,	O
34	O
(	O
14	O
.	O
9	O
%	O
)	O
oropharyngeal	O
SCC	O
,	O
31	O
(	O
13	O
.	O
6	O
%	O
)	O
laryngeal	O
SCC	O
,	O
21	O
(	O
9	O
.	O
2	O
%	O
)	O
hypopharyngeal	O
SCC	O
,	O
and	O
5	O
(	O
2	O
.	O
2	O
%	O
)	O
lip	O
and	O
paranasal	O
sinus	O
SCC	O
.	O

High	O
-	O
risk	O
HPV	O
infection	O
was	O
found	O
in	O
7	O
.	O
5	O
%	O
(	O
17	O
/	O
228	O
)	O
of	O
HNSCC	O
,	O
but	O
only	O
a	O
small	O
proportion	O
of	O
samples	B-HPV_Sample_Type
had	O
evidence	O
of	O
viral	O
integration	O
(	O
5	O
.	O
3	O
%	O
,	O
12	O
/	O
228	O
)	O
or	O
E6	O
/	O
7	O
mRNA	O
expression	O
(	O
4	O
.	O
4	O
%	O
,	O
10	O
/	O
228	O
)	O
.	O

HPV	O
infection	O
with	O
oncogenic	O
phenotype	O
(	O
integration	O
and	O
E6	O
/	O
7	O
mRNA	O
expression	O
)	O
was	O
significantly	O
more	O
common	O
in	O
oropharyngeal	O
SCC	O
than	O
controls	O
(	O
9	O
/	O
34	O
,	O
26	O
.	O
5	O
%	O
vs	O
.	O
0	O
/	O
42	O
,	O
0	O
.	O
0	O
%	O
,	O
Pâ€‰	O
<	O
â€‰0	O
.	O
001	O
)	O
.	O

Smoking	O
showed	O
a	O
significant	O
association	O
with	O
HNSCC	O
,	O
oropharyngeal	O
SCC	O
,	O
and	O
laryngeal	O
SCC	O
.	O

TP53	O
mutation	O
was	O
associated	O
with	O
HNSCC	O
(	O
Pâ€‰	O
<	O
â€‰0	O
.	O
001	O
)	O
.	O

Older	O
age	O
,	O
TP53	O
mutation	O
,	O
and	O
HPV16	O
infection	O
with	O
oncogenic	O
phenotypes	O
were	O
independently	O
associated	O
factors	O
for	O
HNSCC	O
with	O
odds	O
ratios	O
of	O
1	O
.	O
03	O
(	O
1	O
.	O
02	O
-	O
1	O
.	O

05	O
)	O
,	O
3	O
.	O
38	O
(	O
1	O
.	O
71	O
-	O
6	O
.	O

66	O
)	O
,	O
and	O
9	O
.	O
19	O
(	O
1	O
.	O
13	O
-	O
74	O
.	O

68	O
)	O
,	O
respectively	O
.	O

High	O
-	O
risk	O
HPV	O
infection	O
of	O
head	O
and	O
neck	O
mucosa	O
is	O
not	O
uncommon	O
in	O
the	O
Hong	O
Kong	O
population	O
.	O

This	O
study	O
found	O
that	O
26	O
-	O
30	O
%	O
of	O
oropharyngeal	O
carcinoma	O
was	O
associated	O
with	O
HPV	O
infection	O
,	O
mostly	O
HPV16	O
,	O
and	O
that	O
smoking	O
which	O
predisposes	O
to	O
TP53	O
mutations	O
was	O
another	O
important	O
risk	O
factor	O
.	O

%	O
%	O
METHODS	O

Patient	O
Recruitment	O

A	B-Study_Type
multicenter	I-Study_Type
cross	I-Study_Type
-	I-Study_Type
sectional	I-Study_Type
case	I-Study_Type
-	I-Study_Type
control	I-Study_Type
study	I-Study_Type
was	O
conducted	O
from	O
January	B-Study_Time
2012	I-Study_Time
to	I-Study_Time
Decem	I-Study_Time
-	I-Study_Time
ber	I-Study_Time
2014	I-Study_Time
.	I-Study_Time

Patients	B-Study_Cohort
with	I-Study_Cohort
a	I-Study_Cohort
suspected	I-Study_Cohort
benign	I-Study_Cohort
or	I-Study_Cohort
malignant	I-Study_Cohort
lesion	I-Study_Cohort
of	I-Study_Cohort
the	I-Study_Cohort
head	I-Study_Cohort
and	I-Study_Cohort
neck	I-Study_Cohort
mucosa	I-Study_Cohort
were	O
invited	O
to	O
participate	O
.	O

Nasopharyngeal	O
carcinoma	O
was	O
excluded	O
as	O
a	O
known	O
viral	O
etiology	O
,	O
Epstein–	O
Barr	O
virus	O
,	O
has	O
been	O
established	O
.	O

Recurrent	O
cancers	O
and	O
metastases	O
from	O
a	O
primary	O
site	O
outside	O
of	O
the	O
head	O
and	O
neck	O
region	O
were	O
excluded	O
.	O

Tissue	B-HPV_Sample_Type
sam	I-HPV_Sample_Type
-	I-HPV_Sample_Type
ples	I-HPV_Sample_Type
were	O
collected	O
from	O
the	O
diagnostic	B-HPV_Sample_Collection_Method
biopsy	I-HPV_Sample_Collection_Method
or	O
definitive	B-HPV_Sample_Collection_Method
resection	I-HPV_Sample_Collection_Method
.	O

When	O
fresh	O
tissue	B-HPV_Sample_Type
was	O
not	O
available	O
,	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissues	B-HPV_Sample_Type
were	O
used	O
.	O

A	O
written	O
informed	O
consent	O
was	O
ob	O
-	O
tained	O
from	O
all	O
participants	O
.	O

The	O
study	O
was	O
ap	O
-	O
proved	O
by	O
the	O
Joint	O
CUHK	O
-	O
NTEC	O
Clinical	O
Research	O
Ethics	O
Committee	O
and	O
the	O
respective	O
ethics	O
commit	O
-	O
tee	O
of	O
the	O
participating	O
hospitals	O
.	O

HPV	O
DNA	O
Detection	O
and	O
Genotyping	O

Total	O
DNA	O
was	O
extracted	O
from	O
fresh	O
frozen	O
tissue	B-HPV_Sample_Type
samples	I-HPV_Sample_Type
using	O
the	O
QIAamp	O
DNA	O
Mini	O
Kit	O
(	O
Qiagen	O
)	O
,	O
while	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	B-HPV_Sample_Type
sam	I-HPV_Sample_Type
-	I-HPV_Sample_Type
ples	I-HPV_Sample_Type
were	O
first	O
dewaxed	O
with	O
two	O
washes	O
of	O
xylene	O
and	O
ethanol	O
prior	O
to	O
DNA	O
extraction	O
using	O
the	O
QIAamp	O
DNA	O
Mini	O
Kit	O
as	O
described	O
previously	O
[	O
Chan	O
et	O
al	O
.	O
,	O
2001	O
,	O
2009	O
]	O
.	O

The	O
length	O
and	O
quality	O
of	O
extracted	O
DNA	O
preparations	O
were	O
assessed	O
by	O
PCR	B-HPV_Lab_Technique
targeting	O
the	O
housekeeping	O
gene	O
,	O
beta	O
-	O
globin	O
[	O
Chan	O
et	O
al	O
.	O
,	O
2001	O
]	O
.	O

The	O
presence	O
of	O
HPV	O
DNA	O
was	O
detected	O
by	O
nested	B-HPV_Lab_Technique
consensus	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
using	O
primers	O
PGMY09	O
/	O
11	O
and	O
GP5	O
/	O
6	O
_	O
HK52	O
modified	O
from	O
the	O
published	O
methodology	O
[	O
Chan	O
et	O
al	O
.	O
,	O
2001	O
]	O
.	O

Positive	O
amplicons	O
were	O
sequenced	O
and	O
the	O
HPV	O
type	O
was	O
identified	O
based	O
on	O
more	O
than	O
95	O
%	O
homology	O
with	O
the	O
reference	O
sequence	O
available	O
in	O
GenBank	O
.	O

HPV	O
E6	O
/	O
E7	O
mRNA	O
Expression	O

To	O
assist	O
with	O
the	O
analysis	O
of	O
the	O
oncogenic	O
role	O
of	O
high	O
-	O
risk	O
HPVs	O
found	O
,	O
the	O
expression	O
of	O
mRNA	O
encoded	O
viral	O
oncoproteins	O
E6	O
/	O
E7	O
was	O
examined	O
.	O

As	O
the	O
E6	O
and	O
E7	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
are	O
next	O
to	O
each	O
other	O
,	O
a	O
single	O
strand	O
of	O
pre	O
-	O
mRNA	O
molecule	O
was	O
transcribed	O
from	O
the	O
E6	O
and	O
E7	O
ORFs	O
,	O
which	O
then	O
underwent	O
different	O
patterns	O
of	O
splicing	O
.	O

The	O
most	O
dominant	O
and	O
important	O
spliced	O
E6	O
/	O
E7	O
mRNA	O
was	O
the	O
E6	O
*	O
I	O
mRNA	O
,	O
which	O
was	O
measured	O
in	O
this	O
study	O
.	O

Reverse	O
transcription	O
real	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
time	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
RT	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
qPCR	I-HPV_Lab_Technique
)	O
used	O
were	O
based	O
on	O
primers	O
and	O
probes	O
that	O
were	O
specifically	O
designed	O
to	O
cross	O
the	O
splicing	O
site	O
of	O
E6	O
*	O
I	O
mRNA	O
as	O
shown	O
in	O
Table	O
S1	O
.	O

The	O
reaction	O
contained	O
2	O
ml	O
of	O
purified	O
RNA	O
,	O
0	O
.	O
25	O
ml	O
of	O
Super	O
-	O
Script1	O
III	O
/	O
Platinum1	O
Taq	O
Mix	O
(	O
Life	O
Technologies	O
)	O
,	O

12	O
.	O
5	O
ml	O
of	O
2	O
Reaction	O
Mix	O
in	O
a	O
final	O
reaction	O
volume	O

of	O
25	O
ml	O
.	O

The	O
cycling	O
conditions	O
were	O
50˚C	O
for	O
15	O
min	O
,	O
95˚C	O
for	O
2	O
min	O
,	O
followed	O
by	O
40	O
cycles	O
of	O
95˚C	O
for	O
15	O
sec	O
,	O
and	O
55˚C	O
(	O
for	O
HPV16	O
)	O
or	O
58˚C	O
(	O
for	O
HPV31	O
and	O
HPV52	O
)	O
for	O
30	O
sec	O
using	O
the	O
SuperScript1	O
III	O
Plati	O
-	O
num1	O
One	O
-	O
Step	O
qRT	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
Kit	O
with	O
ROX	O
(	O
Life	O
Technologies	O
)	O
.	O

Fresh	O
frozen	O
tissue	B-HPV_Sample_Type
samples	I-HPV_Sample_Type
were	O
preserved	O
with	O
RNAlater	O
(	O
Life	O
Technologies	O
)	O
,	O
and	O
subjected	O
to	O
RNA	O
extraction	O
by	O
using	O
the	O
QIAGEN	O
RNeasy	O
kit	O
(	O
Qia	O
-	O
gen	O
)	O
.	O

RNA	O
was	O
extracted	O
from	O
formalin	O
-	O
fixed	O
paraf	O
-	O
fin	O
-	O
embedded	O
tissues	B-HPV_Sample_Type
using	O
the	O
QIAGEN	O
RNeasy	O
FFPE	O
kit	O
(	O
Qiagen	O
)	O
.	O

The	O
quality	O
of	O
extracted	O
RNA	O
was	O
assessed	O
by	O
RT	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
qPCR	I-HPV_Lab_Technique
with	O
primers	O
and	O
probe	O
specif	O
-	O
ically	O
targeting	O
the	O
splicing	O
region	O
of	O
mRNA	O
encoded	O
by	O
the	O
housekeeping	O
gene	O
RPS18	O
:	O
(	O
forward	O
primer	O
RPS18	O
-	O
F125	O
)	O
—CCT	O
TTG	O
CCA	O
TCA	O
CTG	O
CCA	O
TT	O
,	O

(	O
reverse	O
primer	O
RPS18	O
-	O
R254	O
)	O
—ACT	O
GGC	O
GTG	O
GAT	O
TCT	O
GCA	O
TAA	O
,	O
(	O
probe	O
RPS18	O
-	O
224P	O
)	O
—50FAM	O
CTG	O
AGG	O
ATG	O
AGG	O
TGG	O
AAC	O
30MGBNFQ	O
.	O

The	O
RT	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique

qPCR	I-HPV_Lab_Technique
reaction	O
was	O
the	O
same	O
as	O
described	O
above	O
.	O

The	O
primer	O
and	O
probe	O
concentrations	O
were	O
0	O
.	O
3	O
mM	O
and	O

0	O
.	O
2	O
mM	O
,	O
respectively	O
.	O

The	O
cycling	O
conditions	O
were	O
50˚C	O
for	O
30	O
min	O
,	O
95˚C	O
for	O
2	O
min	O
,	O
followed	O
by	O
40	O
cycles	O

HPV	O
in	O
Chinese	O
Head	O
and	O
Neck	O
Cancers	O
879	O

of	O
95˚C	O
for	O
15	O
sec	O
and	O
60˚C	O
for	O
30	O
sec	O
using	O
the	O
SuperScript1	B-HPV_Lab_Technique
III	I-HPV_Lab_Technique
Platinum1	I-HPV_Lab_Technique
One	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Step	I-HPV_Lab_Technique
qRT	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
Kit	I-HPV_Lab_Technique
with	I-HPV_Lab_Technique
ROX	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Life	I-HPV_Lab_Technique
Technologies	I-HPV_Lab_Technique
)	O
.	O

HPV	O
Integration	O

In	O
addition	O
to	O
E6	O
/	O
E7	O
mRNA	O
detection	O
,	O
the	O
viral	O
integration	O
status	O
of	O
high	O
-	O
risk	O
HPV	O
types	O
was	O
exam	O
-	O
ined	O
to	O
assist	O
with	O
the	O
assessment	O
of	O
the	O
oncogenic	O
role	O
of	O
HPV	O
.	O

Briefly	O
,	O
viral	O
integration	O
that	O
disrupts	O
the	O
E2	O
ORF	O
of	O
HPV	O
genome	O
results	O
in	O
loss	O
of	O
control	O
on	O
the	O
expression	O
of	O
viral	O
oncogenes	O
E6	O
and	O
E7	O
.	O

By	O
comparing	O
the	O
number	O
of	O
copies	O
of	O
E2	O
and	O
E7	O
genes	O
in	O
a	O
given	O
sample	B-HPV_Sample_Type
,	O
one	O
can	O
estimate	O
the	O
physical	O
status	O
of	O
the	O
viral	O
genome	O
.	O

In	O
this	O
study	O
,	O
qPCR	B-HPV_Lab_Technique
methods	O
adopted	O
from	O
previous	O
studies	O
were	O
applied	O
to	O
quantify	O
the	O
levels	O
of	O
E2	O
and	O
E7	O
genes	O
[	O
Cheung	O
et	O
al	O
.	O
,	O
2006	O
]	O
.	O

The	O
primer	O
sequences	O
used	O
are	O
shown	O
in	O
Table	O
S2	O
.	O

For	O
the	O
purpose	O
of	O
analysis	O
in	O
this	O
study	O
,	O
a	O
10	O
-	O
fold	O
(	O
3	O
threshold	O
cycle	O
,	O
CT	O
)	O
difference	O
in	O
genome	O
copies	O
between	O
E2	O
and	O
E7	O
was	O
regarded	O
as	O
an	O
indication	O
of	O
HPV	O
integration	O
.	O

TP53	O
Mutation	O

DNA	O
extracted	O
from	O
tumor	O
or	O
control	O
tissues	B-HPV_Sample_Type
were	O
used	O
to	O
analyze	O
mutations	O
in	O
the	O
TP53	O
gene	O
.	O

Four	O
primer	O
sets	O
were	O
used	O
to	O
amplify	O
the	O
genomic	O
DNA	O
sequences	O
spanning	O
exons	O
4–9	O
of	O
TP53	O
where	O
the	O
majority	O
of	O
mutations	O
were	O
found	O
(	O
Table	O
S3	O
)	O
.	O

The	O
PCR	B-HPV_Lab_Technique
was	O
conducted	O
in	O
a	O
25	O
-	O
ml	O
reaction	O
mix	O
containing	O
2	O
.	O
5	O
ml	O
of	O
DNA	O
,	O
1	O
.	O
25	O
U	O
of	O
HotstarTaq	O
Plus	O
polymerase	O
(	O
Qiagen	O
)	O
,	O
0	O
.	O
2	O
mM	O
of	O
dNTPs	O
,	O
and	O
0	O
.	O
4	O
mM	O
of	O
primers	O
.	O

The	O
thermal	O
cycling	O
conditions	O
were	O
an	O
initial	O
denaturation	O
at	O
95˚C	O
for	O
5	O
min	O
,	O
followed	O
by	O
40	O
cycles	O
of	O
denaturation	O
at	O
94˚C	O
for	O
1	O
min	O
,	O
primer	O
annealing	O
at	O
60˚C	O
(	O
Exon	O
4	O
and	O
5	O
-	O
6	O
PCR	B-HPV_Lab_Technique
)	O
,	O
or	O
64˚C	O
(	O
Exon	O
7	O
PCR	B-HPV_Lab_Technique
)	O
or	O
55˚C	O
(	O
Exon	O
8	O
-	O
9	O
PCR	B-HPV_Lab_Technique
)	O
for	O
1	O
min	O
,	O
and	O
extension	O
at	O
72˚C	O
for	O
1	O
min	O
,	O
and	O
then	O
a	O
final	O
extension	O
at	O
72˚C	O
for	O
10	O
min	O
.	O

The	O
PCR	B-HPV_Lab_Technique
products	O
were	O
analyzed	O
by	O
electrophoresis	O
using	O
a	O
1	O
.	O
5	O
%	O
agarose	O
gel	O
and	O
visualized	O
using	O
SYBR	O
-	O
SAFE	O
pre	O
-	O
staining	O
method	O
.	O

PCR	B-HPV_Lab_Technique
products	O
were	O
purified	O
with	O
QIAquick	O
PCR	O
Purification	O
kit	O
(	O
Qiagen	O
)	O
,	O
and	O
submitted	O
to	O
a	O
commercial	O
laboratory	O
(	O
Macrogen	O
)	O
for	O
sequencing	O
.	O

Polymorphisms	O
and	O
mutations	O
were	O
de	O
-	O
termined	O
based	O
on	O
the	O
reference	O
sequences	O
available	O
from	O
the	O
International	O
Agency	O
for	O
Research	O
on	O
Can	O
-	O
cer	O
(	O
IARC	O
)	O
TP53	O
database	O

Statistical	O
Analysis	O

Subjects	O
with	O
malignant	O
tumors	O
were	O
grouped	O
according	O
to	O
histological	O
type	O
.	O

For	O
the	O
purpose	O
of	O
analysis	O
,	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
included	O
poorly	O
differentiated	O
carcinoma	O
.	O

Subgroup	O
analyses	O
of	O
malignant	O
cases	O
were	O
performed	O
according	O
to	O
the	O
site	O
of	O
tumor	O
.	O

Salivary	O
gland	O
tumors	O
were	O
separated	O
from	O
HNSCC	O
as	O
they	O
are	O
different	O
in	O
terms	O
of	O
histology	O
and	O
etiology	O
.	O

Subjects	O
with	O
non	O
-	O
malignant	O
lesions	O
including	O
normal	O
or	O
inflammatory	O
lesions	O
were	O

regarded	O
as	O
the	O
“control	O
group”	O
,	O
and	O
further	O
divided	O
according	O
to	O
the	O
site	O
of	O
specimen	B-HPV_Sample_Type
collection	O
.	O

Differ	O
-	O
ences	O
in	O
proportion	O
of	O
categorical	O
variables	O
between	O
cancer	O
groups	O
and	O
the	O
corresponding	O
anatomical	O
site	O
-	O
matched	O
control	O
groups	O
were	O
assessed	O
by	O
x	O
-	O
squared	O
or	O
Fisher’s	O
exact	O
test	O
as	O
appropriate	O
,	O
using	O
the	O
StatCalc	O
program	O
of	O
Epi	O
Info	O
(	O
Version	O
7	O
.	O
0	O
.	O
8	O
.	O

3	O
,	O
Cen	O
-	O
ters	O
for	O
Disease	O
Control	O
and	O
Prevention	O
,	O
Georgia	O
)	O
.	O

Differences	O
in	O
age	O
distribution	O
were	O
assessed	O
by	O
t	O
-	O
test	O
,	O
and	O
independent	O
associations	O
were	O
assessed	O
by	O
logistic	O
regression	O
using	O
SPSS	O
(	O
version	O
20	O
,	O
IBM	O
)	O
.	O

